Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Ozempic maker’s new weight-loss drug works better, but not quite good enough for analysts
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Optometry Advisor1h
FDA Approves Encelto for Macular Telangiectasia Type 2
The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).